Clinical Trial Update: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/IIa open-label dose-escalation and expansion study of oral TSR-011 in patients with advanced solid tumors and lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomas
• Solid Tumors

Drugs mentioned

• TSR-011 (TSR-011)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Solid Tumors, Lymphomas | Phase 1, Phase 2 | Status: COMPLETED